Back
ProShares UltraShort Nasdaq Biotech Vs. Sarepta Therapeutics Industry Stock Comparison
Sell
22
BIS
ProShares UltraShort Nasdaq Biotech
Last Price:
16.75
Seasonality Move:
-7.85%
Buy
52
SRPT
Sarepta Therapeutics
Last Price:
157.93
Seasonality Move:
18.65%
Sell
22
ProShares UltraShort Nasdaq Biotech (BIS)
is a Sell
Is ProShares UltraShort Nasdaq Biotech a Buy, Sell or Hold?
- The current ProShares UltraShort Nasdaq Biotech [BIS] share price is $16.65. The Score for BIS is 22, which is 56% below its historic median score of 50, and infers higher risk than normal.
- BIS is currently trading in the 20-30% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
Buy
52
Sarepta Therapeutics (SRPT)
is a Buy
Is Sarepta Therapeutics a Buy, Sell or Hold?
- The current Sarepta Therapeutics [SRPT] share price is $157.74. The Score for SRPT is 52, which is 4% above its historic median score of 50, and infers lower risk than normal.
- SRPT is currently trading in the 50-60% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a higher than normal reading, suggesting risk levels may be somewhat lower than normal.
BIS Stock Price Chart
What is ProShares UltraShort Nasdaq Biotech's stock price today?
-
The ProShares UltraShort Nasdaq Biotech share price today is $16.65
Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and BIS is experiencing slight buying pressure.
SRPT Stock Price Chart
What is Sarepta Therapeutics's stock price today?
-
The Sarepta Therapeutics share price today is $157.74
Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and SRPT is experiencing slight selling pressure.
BIS Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | -0.36 | Sell |
| Relative Strength Index (14 RSI): | 42.77 | Sell |
| Chaikin Money Flow: | 2676 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (16.57 - 17.77) | Sell |
| Bollinger Bands (100): | (16.95 - 19.09) | Sell |
SRPT Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 8.67 | Buy |
| Relative Strength Index (14 RSI): | 68.69 | Buy |
| Chaikin Money Flow: | -86202 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (114.06 - 147.06) | Buy |
| Bollinger Bands (100): | (118.53 - 137.75) | Buy |
BIS Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 16.73 | Sell |
| 20-day SMA: | 16.96 | Sell |
| 50-day SMA: | 17.97 | Sell |
| 200-day SMA: | 19.72 | Sell |
| 8-day EMA: | 16.66 | Sell |
| 20-day EMA: | 16.98 | Sell |
| 50-day EMA: | 17.57 | Sell |
| 200-day EMA: | 19 | Sell |
SRPT Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 149.53 | Buy |
| 20-day SMA: | 132.97 | Buy |
| 50-day SMA: | 129.56 | Buy |
| 200-day SMA: | 115.84 | Buy |
| 8-day EMA: | 150.26 | Buy |
| 20-day EMA: | 138.97 | Buy |
| 50-day EMA: | 131.58 | Buy |
| 200-day EMA: | 121.41 | Buy |
ProShares UltraShort Nasdaq Biotech Earnings Growth & BIS Earnings Dates
- Analysts estimate an earnings decrease this quarter of $0.00 per share, a decrease next quarter of $0.00 per share, a decrease this year of $0.00 per share, and a decrease next year of $0.00 per share.
Sarepta Therapeutics Earnings Growth & SRPT Earnings Dates
- Analysts estimate an earnings increase this quarter of $2.18 per share, an increase next quarter of $2.65 per share, an increase this year of $6.58 per share, and an increase next year of $8.28 per share.
ProShares UltraShort Nasdaq Biotech Technical Analysis
| Jun 14 | Jun 17 | Jun 18 | Jun 20 | Jun 21 | Jun 24 | Jun 25 | Jun 26 | Jun 27 | Jun 28 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun | ||||||||||
| 14 | 17 | 18 | 20 | 21 | 24 | 25 | 26 | 27 | 28 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Sarepta Therapeutics Technical Analysis
| Jun 14 | Jun 17 | Jun 18 | Jun 20 | Jun 21 | Jun 24 | Jun 25 | Jun 26 | Jun 27 | Jun 28 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun | ||||||||||
| 14 | 17 | 18 | 20 | 21 | 24 | 25 | 26 | 27 | 28 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||